{ "items" : [
    { "id" : "http://webisa.webdatacommons.org/339341377"
      "properties" : {
        "http://www.w3.org/1999/02/22-rdf-syntax-ns#type" : [ "http://www.w3.org/ns/prov#Entity" ] ,
        "http://www.w3.org/ns/prov#value" : [ "Side effects, including anaphylaxis, occurred in 20 percent of patients, and the antitoxin is no longer considered beneficial given the self-limiting course of infant botulism.11 Recently, the California Department of Health Services conducted a five-year clinical investigation of botulinum immune globulin, a human-derived antitoxin for the treatment of infant botulism." ] ,
        "http://www.w3.org/ns/prov#wasQuotedFrom" : [ "aafp.org" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/144482422"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/339341377"] } } }
